Pentoxifylline in treatment of pulmonary sarcoidosis

G. R. Nasretdinova, A. A. Vizel, M. E. Gouryleva, N. B. Amirov (Kazan, Russia)

Source: Annual Congress 2002 - Sarcoidosis
Session: Sarcoidosis
Session type: Poster Discussion
Number: 2749
Disease area: Interstitial lung diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
G. R. Nasretdinova, A. A. Vizel, M. E. Gouryleva, N. B. Amirov (Kazan, Russia). Pentoxifylline in treatment of pulmonary sarcoidosis. Eur Respir J 2002; 20: Suppl. 38, 2749

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Methotrexate in the treatment of the chronic form of pulmonary and extra - pulmonary sarcoidosis
Source: Eur Respir J 2004; 24: Suppl. 48, 712s
Year: 2004

Pentoxifylline and reduced doses of steroids combination in pulmonary sarcoidosis
Source: Eur Respir J 2007; 30: Suppl. 51, 110s
Year: 2007

Pulmonary hypertension associated with sarcoidosis and experience of treatment with pentoxifylline (Vasonite)
Source: Eur Respir J 2006; 28: Suppl. 50, 426s
Year: 2006

Treatment with sildenafil for pulmonary hypertension in pulmonary fibrosis
Source: Eur Respir J 2005; 26: Suppl. 49, 562s
Year: 2005

Long-term treatment of pulmonary hypertension with aerosolized iloprost
Source: Eur Respir J 2001; 17: 8-13
Year: 2001



Rituximab in the treatment of refractory pulmonary sarcoidosis
Source: Eur Respir J 2014; 43: 1525-1528
Year: 2014


Experience with pulmonary selective vasodilator treatment in COPD with severe pulmonary hypertension
Source: Annual Congress 2011 - Pulmonary hypertension in hypoxic lung disease
Year: 2011

Cyclosporine A in the treatment of idiopathic pulmonary fibrosis/usual interstitial pneumonia
Source: Eur Respir J 2002; 20: Suppl. 38, 62s
Year: 2002

IgG4-related disease in pulmonary arterial hypertension on long-term epoprostenol treatment
Source: Eur Respir J 2014; 43: 1516-1519
Year: 2014


RISE-IIP: Riociguat for the treatment of pulmonary hypertension associated with idiopathic interstitial pneumonia
Source: International Congress 2017 – New insights into pulmonary hypertension from recent trials
Year: 2017




Inhaled treprostinil therapy in patients with pulmonary hypertension and parenchymal lung disease
Source: Annual Congress 2011 - Treatment of pulmonary hypertension
Year: 2011

Azathioprine and low-dose prednisone in chronic pulmonary sarcoidosis
Source: Eur Respir J 2005; 26: Suppl. 49, 268s
Year: 2005

Effects of oral dual ERA therapy on pulmonary function testing and 6MWT in patients with idiopathic pulmonary fibrosis and pulmonary hypertension
Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH and associated PH
Year: 2012

Comparison of prednisolone and budesonide in the treatment of pulmonary sarcoidosis
Source: Eur Respir J 2005; 26: Suppl. 49, 80s
Year: 2005

Combination treatment with nintedanib and prednisolone for patients with idiopathic pulmonary fibrosis
Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments
Year: 2018

Effects of pulmonary rehabilitation on systemic and pulmonary inflammation in COPD patients
Source: Annual Congress 2010 - Exercise in COPD
Year: 2010


Intravenous pulse doses of high-dose corticosteroid and cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015

Inhalation therapy of interferon-gamma in patients with idiopathic pulmonary fibrosis
Source: Eur Respir J 2005; 26: Suppl. 49, 266s
Year: 2005

Sildenafil and aerolized iloprost treatment in two cases with primary pulmonary hypertension
Source: Eur Respir J 2005; 26: Suppl. 49, 520s
Year: 2005

Treatment of sarcoidosis – pentoxifylline
Source: International Congress 2019 – Granulomatous disorders: pathogenesis, epidemiology and clinical issues
Year: 2019